Pros and cons of antibiotic therapy for pouchitis

References

• Fazio VW, Ziv Y, Church JM et al. Ileal pouch–anal anastomosis: complications and function in 1005 patients. Ann. Surg.222, 120–127 (1995).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Pouchitis following ileal pouch–anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology107, 1856–1860 (1994).
   PubMed Web of Science ®Google Scholar
• Coffey JC, Winter DC, Neary P et al. Quality of life after ileal pouch–anal anastomosis: an evaluation of diet and other factors using the Cleveland Global Quality of Life instrument. Dis. Colon Rectum45, 30–38 (2002).
   PubMed Web of Science ®Google Scholar
• Stocchi L, Pemberton JH. Pouch and pouchitis. Gastroenterol. Clin. North Am.30, 223–241 (2001).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch–anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin. Proc.69, 409–415 (1994).
   PubMed Web of Science ®Google Scholar
• Keighley MR. Review article: the management of pouchitis. Aliment. Pharmacol. Ther.10, 449–457 (1996).
   PubMed Web of Science ®Google Scholar
• Mowschenson PM, Critchlow JF, Peppercorn MA. Ileoanal pouch operation: long-term outcome with or without diverting ileostomy. Arch. Surg.135, 463–465 (2000).
   PubMedGoogle Scholar
• Hurst RD, Chung TP, Rubin M, Michelassi F. Implications of acute pouchitis on the long-term functional results after restorative proctocolectomy. Inflamm. Bowel Dis.4, 280–284 (1998).
   PubMed Web of Science ®Google Scholar
• Madiba TE, Bartolo DC. Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. J. Royal Coll. Surg. Edinburgh46, 334–337 (2001).
   PubMedGoogle Scholar
• Lohmuller JL, Pemberton HJ, Dozois RR, Ilstrup D, van Heerden J. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch–anal anastomosis. Ann. Surg.211, 622–629 (1990).
   PubMed Web of Science ®Google Scholar
• Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch. Surg.131, 497–500; discussion 501–502 (1996).
   PubMed Web of Science ®Google Scholar
• Ohge H, Furne JK, Springfield J et al. Association between fecal hydrogen sulfide production and pouchitis. Dis. Colon Rectum48, 469–475 (2005).
   PubMed Web of Science ®Google Scholar
• Gosselink MP, Schouten WR, van Lieshout LM et al. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis. Colon Rectum47, 1519–1525 (2004).
   PubMed Web of Science ®Google Scholar
• Shen B, Fazio VW, Remzi FH et al. Risk factors for diseases of ileal pouch–anal anastomosis in patients with ulcerative colitis. Clin. Gastroenterol. Hepatol.4, 81–89 (2006).
   PubMed Web of Science ®Google Scholar
• Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig. Dis. Sci.39, 1193–1196 (1994).
   PubMed Web of Science ®Google Scholar
• Shen B, Achkar JP, Lashner BA et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm. Bowel Dis.7, 301–305 (2001).
   PubMed Web of Science ®Google Scholar
• Sambuelli A, Boerr L, Negreira S et al. Budesonide enema in pouchitis – a double-blind, double-dummy, controlled trial. Aliment. Pharmacol. Ther.16, 27–34 (2002).
   PubMed Web of Science ®Google Scholar
• Kühbacher T, Ott SJ, Helwig U et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut55, 833–841 (2006).
   PubMed Web of Science ®Google Scholar
• Shen B, Jiang Z-D, Fazio VW et al.Clostridium difficile infection in patients with ileal pouch–anal anastomosis. Clin. Gastroenterol. Hepatol.6, 782–788 (2008).
   PubMed Web of Science ®Google Scholar
• Penna C, Tiret E, Kartheuser A, Hannoun L, Nordlinger B, Parc R. Function of ileal J pouch–anal anastomosis in patients with familial adenomatous polyposis. Br. J. Surg.80, 765–767 (1993).
   PubMed Web of Science ®Google Scholar
• Tjandra JJ, Fazio VW, Church JM, Oakley JR, Milsom JW, Lavery IC. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am. J. Surg.165, 322–325 (1993).
   PubMed Web of Science ®Google Scholar
• Coffey JC, Rowan F, Burke J, Dochery NG, Kirwan WO, O’Connell PR. Pathogenesis of and unifying hypothesis for idiopathic pouchitis. Am. J. Gastroenterol.104, 1013–1023 (2009).
   PubMed Web of Science ®Google Scholar
• Shepherd NA, Jass JR, Duval I et al. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J. Clin. Pathol.40, 601–607 (1987).
   PubMed Web of Science ®Google Scholar
• Humphries DE, Silbert CK, Silbert JE. Glycosaminoglycan production by bovine aortic endothelial cells cultured in sulfate-depleted medium. J. Biol. Chem.261, 9122–9127 (1986).
   PubMed Web of Science ®Google Scholar
• Smith FM, Coffey JC, Kell MR et al. A characterization of anaerobic colonization and associated mucosal adaptations in the undiseased ileal pouch. Colorectal Dis.7, 563–570 (2005).
   PubMed Web of Science ®Google Scholar
• Kmiot WA, Williams MR, Keighley MR. Pouchitis following colectomy and ileal reservoir construction for familial adenomatous polyposis. Br. J. Surg.77, 1283 (1990).
   PubMed Web of Science ®Google Scholar
• Ohge H, Takesue Y, Sueda T et al. [Fecal hydrogen sulfide: toxin? Or just odoriferous gas?]. Jpn. J. Antibiotics58, 193–199 (2005).
   PubMedGoogle Scholar
• de Silva HJ, Gatter KC, Millard PR et al. Crypt cell proliferation and HLA-DR expression in pelvic ileal pouches. J. Clin. Pathol.43, 824–828 (1990).
   PubMed Web of Science ®Google Scholar
• Deplancke B, Finster K, Graham WV et al. Gastrointestinal and microbial responses to sulfate-supplemented drinking water in mice. Exp. Biol. Med. (Maywood)228, 424–433 (2003).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Pouchitis: risk factors, frequency, natural history, classification and public health prospective. In: Trends in Inflammatory Bowel Disease 1996. McLeod RS, Martin F, Sutherland LR, Wallace JL, Williams CN (Eds). Kluwer Academic Publishers, Lancaster, UK, 51–63 (1997).
   Google Scholar
• Shen B. Diagnosis and management of patients with pouchitis. Drugs65, 453–461 (2003).
   Google Scholar
• Duffy M, O’Mahony L, Coffey JC et al. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis. Colon Rectum45, 384–388 (2002).
   PubMed Web of Science ®Google Scholar
• Komanduri S, Gillevet PM, Sikaroodi M et al. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin. Gastroenterol. Hepatol.5, 352–360 (2007).
   PubMed Web of Science ®Google Scholar
• Shen B, Fazio VW, Remzi FH et al. Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouch–anal anastomoses. Am. J. Gastroenterol.100, 93–101 (2005).
   PubMed Web of Science ®Google Scholar
• Shepherd NA, Hulten L, Tytgat GN et al. Workshop: pouchitis. Int. J. Colorectal Dis.4, 205–229 (1989).
   PubMed Web of Science ®Google Scholar
• Sagar PM, Pemberton JH. Ileo–anal pouch function and dysfunction. Dig. Dis.15, 172–188 (1997).
   PubMed Web of Science ®Google Scholar
• Kmiot WA, Youngs D, Tudor R, Thompson H, Keighley MR. Mucosal morphology, cell proliferation and fecal bacteriology in acute pouchitis. Br. J. Surg.80, 1445–1449 (1993).
   PubMed Web of Science ®Google Scholar
• Bell AJ, Nicholls RJ, Forbes A, Ellis HJ, Ciclitira PJ. Human lymphocyte stimulation with pouchitis flora is greater than with flora from a healthy pouch but is suppressed by metronidazole. Gut53, 1801–1805 (2004).
   PubMed Web of Science ®Google Scholar
• Sagar PM, Taylor BA, Godwin P et al. Acute pouchitis and deficiencies of fuel. Dis. Colon Rectum38, 488–493 (1995).
   PubMed Web of Science ®Google Scholar
• Koo HL, DuPont HL. Current and future developments in travelers’ diarrhea therapy. Expert Rev. Anti Infect. Ther.4, 417–427 (2006).
   PubMedGoogle Scholar
• Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion73(Suppl. 1), 13–27 (2006).
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion66, 246–245 (2002).
   PubMed Web of Science ®Google Scholar
• Riva S, Fietta A, Berti M, Silvestri LG, Romero E. Relationships between curing of the F episome by rifampin and by acridine orange in Escherichia coli. Antimicrob. Agents Chemother.3, 456–462 (1973).
   PubMed Web of Science ®Google Scholar
• Huang DB, DuPont HL. Rifaximin – a novel antimicrobial for enteric infections. J. Infect.50, 97–106 (2005).
   PubMed Web of Science ®Google Scholar
• Isaacs KL, Sandler RS, Abreu M et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm. Bowel Dis.13, 1250–1255 (2007).
   PubMed Web of Science ®Google Scholar
• Baidoo L, Kundu R, Su C et al. Rifaximin is an effective antibiotic for the treatment of pouchitis [abstract]. Gastroenterology128(4 Suppl. 2), A797 (2005).
   PubMedGoogle Scholar
• McLaughlin SD, Clark SK, Bell AJ, Tekkis PP, Ciclitira PJ, Nicholls RJ. An open study of antibiotics for the treatment of pre-pouch ileitis following restorative proctocolectomy with ileal pouch–anal anastomosis. Aliment. Pharmacol. Ther.29(1), 69–74 (2008).
   PubMed Web of Science ®Google Scholar
• Mimura T, Rizzello F, Helwig U et al. Once daily high dose probiotic therapy (VSL#3®) for maintaining remission in recurrent or refractory pouchitis. Gut53, 108–114 (2004).
   PubMed Web of Science ®Google Scholar
• Shen B, Brzezinski A, Fazio VW et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis – experience in clinical practice. Aliment. Pharmacol. Ther.22, 721–728 (2005).
   PubMed Web of Science ®Google Scholar
• McLaughlin SD, Johnson MW, Clark SK, Tekkis PP, Ciclitira PJ, Nicholls RJ. VSL#3 for chronic pouchitis; experience in UK clinical practice [abstract]. Gastroenterology134(Suppl. 1), A711 (2008).
   Google Scholar
• Shen B, Remzi FH, Lopez AR, Queener E. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol.8, 26 (2008).
   PubMed Web of Science ®Google Scholar
• Shen B, Fazio VW, Remzi FH et al. Effect of withdrawal of nonsteroidal anti-inflammatory drug use on ileal pouch disorders. Dig. Dis. Sci.52, 3321–3328 (2007).
   PubMed Web of Science ®Google Scholar
• Munoz-Juarez M, Pemberton JH, Sandborn WJ, Tremaine WJ, Dozois RR. Misdiagnosis of specific cytomegalovirus infection of ileoanal pouch as a refractory idiopathic chronic pouchitis. Report of two cases. Dis. Colon Rectum42, 117–120 (1999).
   PubMed Web of Science ®Google Scholar
• Shen B, Remzi FH, Nutter B et al. Association between immune-associated disorders and adverse outcomes of ileal pouch–anal anastomosis. Am. J. Gastroenterol.104, 655–664 (2009).
   PubMed Web of Science ®Google Scholar
• McLaughlin SD, Clark SK, Shafi S et al. Fecal coliform testing to identify effective antibiotic therapies for patients with antibiotic-resistant pouchitis. Clin. Gastroenterol. Hepatol.7, 545–548 (2009).
   PubMed Web of Science ®Google Scholar
• Shen B, Fazio V, Remzi F et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis. Col. Rectum50, 498–508 (2007).
   PubMed Web of Science ®Google Scholar
• Mimura T, Rizzello F, Helwig U et al. Four-week open label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment. Pharmacol. Ther.16, 909–917 (2002).
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment. Pharmacol. Ther.13, 713–718 (1999).
   PubMed Web of Science ®Google Scholar
• Abdelrazeq AS, Kelly SM, Lund JN, Leveson SH. Rifaximin–ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis.7, 182–186 (2005).
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Hunt M, George J, Legnani P. An open label pilot trial of rifaximin in the treatment of patients with refractory pouchitis [abstract]. Gastroenterology130(4 Suppl. 2), A658 (2006).
   Google Scholar
• Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology124, 1202–1209 (2003).
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology119, 305–309 (2000).
   PubMed Web of Science ®Google Scholar
• Pronio A, Montesani C, Butteroni C et al. Probiotic administration in patients with ileal pouch–anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm. Bowel Dis.14, 662–668 (2008).
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Poggioli G et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment. Pharmacol. Ther.25, 1231–1236 (2007).
   PubMed Web of Science ®Google Scholar
• Calabrese C, Gionchetti P, Rizzello F et al. Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment. Pharmacol. Ther.27, 759–764 (2008).
   PubMed Web of Science ®Google Scholar
• Viscido A, Kohn A, Papi C, Caprilli R. Management of refractory fistulizing pouchitis with infliximab. Eur. Rev. Med. Pharmacol. Sci.8, 239–246 (2004).
   PubMedGoogle Scholar
• Shen B, Remzi FH, Lavery IC et al. Administration of adalimumab in the treatment of Crohn’s disease of the ileal pouch. Aliment. Pharmacol. Ther.29, 519–526 (2009).
   PubMed Web of Science ®Google Scholar
• Wischmeyer P, Pemberton JH, Phillips SF. Chronic pouchitis after ileal pouch–anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study. Mayo Clin. Proc.68, 978–981 (1993).
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A et al. Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis. Aliment. Pharmacol. Ther.11, 673–678 (1997).
   PubMed Web of Science ®Google Scholar
• Tremaine WJ, Sandborn WJ, Wolff BG, Carpenter HA, Zinsmeister AR, Metzger PP. Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. Aliment. Pharmacol. Ther.11, 1041–1046 (1997).
   PubMed Web of Science ®Google Scholar
• Kapoor K, Chandra M, Nag D et al. Evaluation of metronidazole toxicity: a prospective study. Int. J. Clin. Pharmacol. Res.19, 83–88 (1999).
   PubMedGoogle Scholar
• Raether W, Hänel H. Nitroheterocyclic drugs with broad-spectrum activity. Parasitol. Res.90(Suppl.), 19–39 (2003).
   PubMed Web of Science ®Google Scholar
• Mann SD, Pitt J, Springall RG, Thillainayagam AV. Clostridium difficile infection – an unusual cause of refractory pouchitis: report of a case. Dis. Colon Rectum46, 267–270 (2003).
   PubMed Web of Science ®Google Scholar
• Shen B, Goldblum JR, Hull TL, Remzi FH, Bennett AE, Fazio VW. Clostridium difficile-associated pouchitis. Dig. Dis. Sci.51, 2361–2364 (2006).
   PubMed Web of Science ®Google Scholar
• Fung HB, Doan TL. Tinidazole: a nitroimidazole antiprotozoal agent. Clin. Ther.27, 1859–1884 (2005).
   PubMed Web of Science ®Google Scholar
• Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev.61, 377–392 (1997).
   PubMed Web of Science ®Google Scholar
• Mandell LA. Improved safety profile of newer fluoroquinolone. In: Fluoroquinolone Antibiotics. Ronald AR, Low DE (Eds). Birkhäuser, Basel, Switzerland, 73–86 (2003).
   Google Scholar
• Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis.41, 1254–1260 (2005).
   PubMed Web of Science ®Google Scholar
• Soro O, Pesce A, Raggi M, Debbia EA, Schito GC. Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin. Clin. Microbiol. Infect.3, 147—51 (1997).
   PubMedGoogle Scholar
• Malvisi Stracciari J, Venturini AP, Anfossi P, Marchi E, Stracciari GL. Sensitivity to rifaximin and rifampicin of Mycobacterium tuberculosis isolated from guinea pigs treated orally with rifaximin. Chemioterapia6, 82–84 (1987).
   PubMedGoogle Scholar
• Shen B, Achkar J-P, Lashner BA et al. Endoscopic and histologic evaluation together with symptom assessment is required to diagnose pouchitis. Gastroenterology121, 261–267 (2001).
   PubMed Web of Science ®Google Scholar
• Shen B, Achkar JP, Lashner BA et al. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch–anal anastomosis. Am. J. Gastroenterol97, 972–977 (2002).
   PubMed Web of Science ®Google Scholar
• Shen B, Shermock KM, Fazio VW et al. A cost–effectiveness analysis of diagnostic strategies for symptomatic patients with ileal pouch–anal anastomosis. Am. J. Gastroenterol.98, 2460–2467 (2003).
   PubMed Web of Science ®Google Scholar